Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2023 07:00 ET | Source: Humacyte, Inc.

Humacyte and Oberland Capital Announce Funding Arrangement Totaling Up to $160 Million

- $40 million upfront, $20 million upon FDA acceptance of HAV BLA in vascular trauma, $40 million upon FDA approval of HAV in vascular trauma, $50 million upon achievement of certain sales milestones,...
May 09, 2023 08:00 ET | Source: Humacyte, Inc.

Humacyte Announces Publication in Lancet Regional Health - Europe Presenting Use of Human Acellular Vessel™ (HAV™) to Treat Vascular Injuries in Ukraine

First regenerative medicine technology used in battlefield trauma Ukrainian surgeons trained on HAV procedures over video conferencing DURHAM, N.C., May 09, 2023 (GLOBE NEWSWIRE) --...
May 05, 2023 08:00 ET | Source: Humacyte, Inc.

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023

DURHAM, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
May 04, 2023 08:00 ET | Source: Humacyte, Inc.

Humacyte’s Human Acellular Vessel™ (HAV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma

HAV granted second RMAT designation by the FDARMAT will support Humacyte’s lead indication in Vascular Trauma DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a...
April 28, 2023 08:00 ET | Source: Humacyte, Inc.

Humacyte to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

DURHAM, N.C., April 28, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
April 27, 2023 08:00 ET | Source: Humacyte, Inc.

Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes

NEW YORK, N.Y. and DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company pioneering the development and manufacturing of off-the-shelf, universally...
April 18, 2023 08:00 ET | Source: Humacyte, Inc.

Humacyte Announces Publication of Preclinical Study Comparing Human Acellular Vessel™ (HAV™) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma

Results published in Journal of Trauma and Acute Care Surgery Company also provides update on enrollment progress in Phase 2/3 vascular trauma trial DURHAM, N.C., April 18, 2023 (GLOBE...
April 11, 2023 08:00 ET | Source: Humacyte, Inc.

Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients

DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
August 26, 2021 16:05 ET | Source: Humacyte, Inc.

Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under “HUMA” and “HUMAW” on August 27, 2021Company well-positioned to deliver on...
August 24, 2021 12:58 ET | Source: Humacyte, Inc.

Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte

NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its stockholders...